TGTX — TG Therapeutics Share News
0.000.00%
Last trade - 00:00- $8.57bn
- $8.77bn
- $616.29m
TG Therapeutics jumps on 2026 revenue outlook, prelim 2025 sales beat
TG Therapeutics jumps after preliminary 2025 sales exceed forecast
Brief: Tg Therapeutics Provides Preliminary Fourth Quarter And Full Year 2025 Results
TG Therapeutics Q3 revenue up on strong demand, raises 2025 forecast
Brief: TG Therapeutics Completes Enrollment In The Phase 3 Enhance Trial Evaluating Its New Simplified Dosing Schedule For Briumvi
Brief: TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment
Brief: TG Therapeutics Files For Mixed Shelf Offering, Size Not Disclosed - Filing
TG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
TG Therapeutics Q2 revenue soars, helped by BRIUMVI sales
TG Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
TG Therapeutics Inc expected to post earnings of 18 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-THOR Industries, TG Therapeutics, Target
TG Therapeutics rises on quarterly net product revenue beat
TG Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
TG Therapeutics Inc expected to post earnings of 8 cents a share - Earnings Preview
Brief: TG Therapeutics Announces Schedule Of Data Presentations For Briumvi® (Ublituximab) In Multiple Sclerosis At The Americas Committee For Treatment And Research In Multiple Sclerosis Annual Forum
U.S. STOCKS ON THE MOVE-Fortinet, KB Home, Goldman Sachs
U.S. STOCKS ON THE MOVE-Teladoc Health, Mustang Bio, Instacart
U.S. STOCKS ON THE MOVE-B Riley, H&E Equipment, Emergent BioSolutions